Brokerages expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to post earnings of ($4.38) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for BeiGene’s earnings. The lowest EPS estimate is ($4.45) and the highest is ($4.30). BeiGene posted earnings per share of ($5.23) during the same quarter last year, which would suggest a positive year over year growth rate of 16.3%. The business is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that BeiGene will report full year earnings of ($15.13) per share for the current fiscal year, with EPS estimates ranging from ($17.44) to ($12.37). For the next fiscal year, analysts expect that the company will report earnings of ($11.85) per share, with EPS estimates ranging from ($16.87) to ($7.49). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover BeiGene.
BeiGene (NASDAQ:BGNE – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($4.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.12) by ($0.12). The business had revenue of $306.60 million for the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative net margin of 218.25% and a negative return on equity of 40.10%. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year.
In other news, COO Xiaobin Wu sold 6,725 shares of BeiGene stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $164.35, for a total value of $1,105,253.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.90% of the company’s stock.
A number of large investors have recently modified their holdings of BGNE. O Shaughnessy Asset Management LLC lifted its position in BeiGene by 204.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 70 shares of the company’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. Pinebridge Investments L.P. bought a new stake in BeiGene in the 4th quarter valued at about $27,000. Koshinski Asset Management Inc. lifted its position in BeiGene by 139.6% in the 1st quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock valued at $46,000 after purchasing an additional 141 shares during the last quarter. Marshall Wace North America L.P. bought a new stake in shares of BeiGene during the 1st quarter worth about $76,000. Finally, Assetmark Inc. raised its position in shares of BeiGene by 25.2% during the 3rd quarter. Assetmark Inc. now owns 288 shares of the company’s stock worth $105,000 after buying an additional 58 shares in the last quarter.
BGNE stock traded up $1.39 during midday trading on Friday, reaching $132.87. 424,882 shares of the company’s stock traded hands, compared to its average volume of 237,811. The company has a market capitalization of $13.64 billion, a P/E ratio of -6.61 and a beta of 0.85. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.05 and a quick ratio of 4.61. BeiGene has a fifty-two week low of $120.00 and a fifty-two week high of $426.56. The business has a 50-day moving average price of $175.89 and a two-hundred day moving average price of $241.52.
About BeiGene (Get Rating)
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.